Literature DB >> 7493610

Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities.

D S Kreiss1, D A Bergstrom, A M Gonzalez, K X Huang, D R Sibley, J R Walters.   

Abstract

The potencies for in vivo inhibition of substantia nigra pars compacta dopamine single cell firing were determined for apomorphine, BHT 920, N-0923, (+/-)-7-hydroxy-dipropylaminotetralin (7-OH-DPAT), (+)-3-(3-hydroxyphenyl)-N-propylpiperidine (3-PPP), pramipexole, quinelorane, quinpirole, RU 24926, U-86170, and U-91356. Significant correlation was obtained between the potencies of these 11 highly efficacious dopamine receptor agonists and the in vitro binding affinities at dopamine D3 receptors, but not at dopamine D2L receptors. These results support a functional role for the dopamine D3 receptor subtype in the autoreceptor-mediated regulation of dopamine cell activity, while a role for dopamine D2 receptors awaits further analysis. In addition, the results demonstrate the limitations of using currently available dopamine receptor agonists to delineate relative in vivo roles for the dopamine D2 and D3 receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493610     DOI: 10.1016/0014-2999(95)00069-w

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Functional roles of dopamine D2 and D3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo.

Authors:  J M Tepper; B C Sun; L P Martin; I Creese
Journal:  J Neurosci       Date:  1997-04-01       Impact factor: 6.167

Review 2.  Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice.

Authors:  T E Koeltzow; M Xu; D C Cooper; X T Hu; S Tonegawa; M E Wolf; F J White
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

3.  Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.

Authors:  M M Pinter; O Pogarell; W H Oertel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-04       Impact factor: 10.154

4.  Antagonism of the effects of (+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626.

Authors:  B J Bowery; Z Razzaque; F Emms; S Patel; S Freedman; L Bristow; J Kulagowski; G R Seabrook
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

5.  Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors.

Authors:  Francoise Rouge-Pont; Alessandro Usiello; Marianne Benoit-Marand; Francois Gonon; Pier Vincenzo Piazza; Emiliana Borrelli
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

Review 6.  Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.

Authors:  Gerhard Gross; Karsten Wicke; Karla U Drescher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-06       Impact factor: 3.000

7.  Cocaine self-administration in dopamine D₃ receptor knockout mice.

Authors:  S Barak Caine; Morgane Thomsen; Andrew C Barrett; Gregory T Collins; Peter Grundt; Amy Hauck Newman; Paul Butler; Ming Xu
Journal:  Exp Clin Psychopharmacol       Date:  2012-08-06       Impact factor: 3.157

8.  In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.

Authors:  K Hidaka; S Tada; M Matsumoto; J Ohmori; Y Tasaki; T Nomura; S Usuda; T Yamaguchi
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.